BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//pretalx//sciencenext.org//ifos2026//DQAJW3
BEGIN:VTIMEZONE
TZID:EET
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20061029T000000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20071028T050000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20141026T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20151108T050000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=11;UNTIL=20151108T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20160907T010000
RRULE:FREQ=YEARLY;BYDAY=1WE;BYMONTH=9
TZNAME:+03
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20060326T000000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20070325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20100328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20110328T040000
RRULE:FREQ=YEARLY;BYDAY=4MO;BYMONTH=3;UNTIL=20110328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20120325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20130331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20140331T040000
RRULE:FREQ=YEARLY;BYDAY=5MO;BYMONTH=3;UNTIL=20140331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20150329T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20160327T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:pretalx-ifos2026-RS9LZU@sciencenext.org
DTSTART;TZID=EET:20260912T070000
DTEND;TZID=EET:20260912T080000
DESCRIPTION:Early tumors are usuall
y treated with
monotherapy: en
doscopic laser resection\,
ope
n partial laryngectomy or radiotherapy\,
with a good oncological prognosis.
Currently\, endoscopic laser resection and
radiotherapy are the preferred options\,
with a higher risk of salvage tota
l laryngectomy
and higher trea
tment costs when radiotherapy
is used. For tumors staged as T3\,
if the surgical option is total laryngectomy\,
a non-surgical organ preservation protocol
with the combination of radiotherapy an
d
chemotherapy may be indicate
d.
With this\, in most cases\,
larynx preservation
is achiev
ed. However\, anatomical preservation
often does not correspond to functional preservation.
If the surgical option is partial laryngec
tomy\,
both organ preservation
options should
be considered:
surgical (partial laryngectomy)
or non-surgical. For more advanced tumors (T4)\,
total laryngectomy is the option with
the best oncological results\, despite the <
/p>
mutilation caused by the defini
tive tracheotomy.
The aim of t
his symposium is to critically discuss
the various therapeutic options for laryngeal cancer.
DTSTAMP:20260813T210852Z
LOCATION:Phoniatrics 3
SUMMARY:Treatment approaches in laryngeal cancer - Rogerio A. Dedivitis\,
Mark Zafereo\, Luiz P. Kowalski\, Alirio Mijares Brinez\, Gabriel Damiano\
, Paul Boettinger
URL:https://sciencenext.org/ifos2026/talk/RS9LZU/
END:VEVENT
END:VCALENDAR